Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.

“We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,” said Paul Moore, Chief Scientific Officer of Zymeworks. “ZW171’s unique design is intended to address the limitations of current bispecific T-cell engagers by enhancing tumor selectivity and improving safety. With promising preclinical results, ZW171 has the potential to provide a more effective and tolerable treatment option for patients with MSLN-expressing cancers, including ovarian cancer, non-small cell lung cancer, mesothelioma, and other cancers1. We look forward to initiating clinical development of ZW171 during 2024 and continuing to advance additional product candidates in our ‘5 by 5’ strategy over the next 24 months.”

The Company expects to file applications seeking regulatory permission to commence clinical studies for ZW171 in other non-US jurisdictions in the second half of 2024.

ZW171 is a bispecific antibody designed to enable T cell-mediated tumor cell killing through simultaneous binding to the extracellular domain of MSLN protein on tumor cells and the engagement of CD3 on T cells. Moderate to high membranous MSLN expression is frequent in ovarian cancer, non-small cell lung cancer, mesothelioma and other cancers1. Preliminary evidence of anti-tumor activity with engineered T-cell therapy supports utility of T-cell targeted therapies in treatment of MSLN-expressing solid tumors2. ZW171’s unique 2+1 format and incorporation of a novel low-affinity anti-CD3 binder aims to improve the therapeutic window in patients by limiting on-target, off-tumor effects and cytokine release syndrome (CRS) while maintaining potent anti-tumor activity against MSLN-expressing cancers3. By selectively binding to tumors and sparing normal tissues, ZW171 is designed to improve both tolerability and anti-tumor activity against MSLN-expressing cancers. Engineered and optimized using our Azymetric™ and EFECT™4 technologies, ZW171 demonstrates enhanced anti-tumor activity and safety in preclinical models, inducing potent, preferential killing of MSLN-overexpressing cells while mitigating the risk of on-target, off-tumor activity, peripheral T cell activation, and CRS.

1. Chang K, Pastan I, Proc Natl Acad Sci U S A. 1996;93(1):136-40
2. Hassan R, et al. Nat Med. 2023;29:2099-2109
3. 1. Wang L, et al., Cancer Immunol Res. 2019; 7(12): 2013–2024
4. Afacan N, et al. Presented at: AACR. 2023 (abstr #2942)

About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential addressable market of Zymeworks’ preclinical candidates; Zymeworks’ development of its preclinical candidates; the timing and status of ongoing and future studies and the related data; expectations and timing regarding future regulatory filings and approvals; the timing of and results of interactions with regulators; potential safety profile and therapeutic effects of zanidatamab and Zymeworks’ other product candidates; the commercial potential of technology platforms and product candidates and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com


Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

THỦ THUẬT HAY

5 cách khắc phục lỗi camera trước của điện thoại bị mờ bạn nên biết

Bạn hay sử dụng camera trước của điện thoại để selfie hoặc dùng để quay vlog. Bạn cảm thấy khá thất vọng với chất lượng những bức hình, video mà bạn vừa chụp hoặc quay bị mờ và không có độ sắc nét như lúc ban đầu mà

Dòng CPU Core i9 mới của Intel là gì?

Nhiều năm qua, bộ vi xử lý Core của Intel đã có 3 cấp độ hiệu năng: i3, i5 và đứng đầu là i7. Tuy nhiên, mới đây, Intel đã công bố các phiên bản mới của Intel trong dòng Intel Core i9. Hãy đọc bài viết dưới đây để biết

Cách chụp ảnh hiệu ứng World Cup trên Facebook và Facebook Messenger

Theo thông tin chính thức từ mạng xã hội lớn nhất Thế giới này, trước khi khai mạc World Cup 2018 một ngày, người dùng sẽ nhận được một tin nhắn trên News Feed tài khoản Facebook của mình với nội dung mời họ tham gia

Cách đổi ngôn ngữ trên Facebook Messenger dành cho người dùng Android và iOS

Nếu bạn muốn thay đổi ngôn ngữ trên Messenger, dưới đây là hướng dẫn nhanh để lựa chọn thay đổi các ngôn ngữ trên Messenger dành cho người dùng Android và iPhone.

Hướng dẫn trải nghiệm tính năng Google Chrome Duplex

Google đang thử nghiệm tính năng mới nhằm hỗ trợ người dùng tốt hơn khi trải nghiệm trình duyệt với một tay, với tính năng Google Chrome Duplex giúp thay đổi giao diện ở thanh toolbar. Trong phiên bản thử nghiệm này,

ĐÁNH GIÁ NHANH

Trên tay Sony SBH24: Tai nghe Bluetooth nhỏ gọn, cổng sạc USB-C

Về thông số kỹ thuật, SBH24 không quá nổi bật so với các mẫu tai nghe cùng tầm giá. Ngay cả chuẩn truyền dữ liệu aptX cũng chưa được Sony đưa vào sản phẩm này.

Asus MB169AC: Màn hình nhẹ, tiết kiệm điện, chất lượng hiển thị cao, giá đắt

Asus MB16AC là dòng màn hình di động cao nhất của Asus ở thời điểm hiện tại, nên không có gì ngạc nhiên khi nó mang thương hiệu ZenScreen, có thiết kế viền siêu mỏng, nặng 780g, dày 8mm

Trên tay LG Gram 2018: Laptop siêu mỏng nhẹ, chip Intel thế hệ thứ 8, 4 nhân vật lý

Tại CES 2018 LG đã ra mắt thế hệ tiếp theo của LG Gram - dòng sản phẩm gây được nhiều tiếng vang trong năm 2017 nhờ thiết kế vô cùng gọn nhẹ với chất liệu cao cấp, thời lượng pin tốt. Năm nay sản phẩm tiếp tục được